Press answerYES Consulting 12/14/20 answerYES Consulting 12/14/20 Thetis Pharmaceuticals Receives Orphan Drug Designation for Resolvin E1 Program in Pediatric Ulcerative Colitis (12/14/2020) Read More answerYES Consulting 7/23/20 answerYES Consulting 7/23/20 Thetis Pharmaceuticals Announces Patent Issuance in Europe for its Resolvin E1 candidate, TP-317, for Inflammatory Bowel Disease (7/23/2020) Read More answerYES Consulting 11/19/19 answerYES Consulting 11/19/19 Thetis Pharmaceuticals Receives Funding from the Crohn’s & Colitis Foundation to Support Investigational Mucosal Healing Therapy for Inflammatory Bowel Disease (11/19/2019) Read More Newer Posts
answerYES Consulting 12/14/20 answerYES Consulting 12/14/20 Thetis Pharmaceuticals Receives Orphan Drug Designation for Resolvin E1 Program in Pediatric Ulcerative Colitis (12/14/2020) Read More
answerYES Consulting 7/23/20 answerYES Consulting 7/23/20 Thetis Pharmaceuticals Announces Patent Issuance in Europe for its Resolvin E1 candidate, TP-317, for Inflammatory Bowel Disease (7/23/2020) Read More
answerYES Consulting 11/19/19 answerYES Consulting 11/19/19 Thetis Pharmaceuticals Receives Funding from the Crohn’s & Colitis Foundation to Support Investigational Mucosal Healing Therapy for Inflammatory Bowel Disease (11/19/2019) Read More